Guelph Scientists Develop First Vaccine to Help Control Autism-Associated Bacteria

300px-Autism_spectrum
Autism spectrum (Photo credit: Wikipedia)

University of Guelph researchers have created a first-ever vaccine for gut bacteria common in autistic children.

The groundbreaking study by Brittany Pequegnat and Guelph chemistry professor Mario Monteiro appears this month in the journal Vaccine.

They developed a carbohydrate-based vaccine against the gut bug

Clostridium bolteae.

C. bolteae is known to play a role in gastrointestinal disorders, and it often shows up in higher numbers in the GI tracts of autistic children than in those of healthy kids.

More than 90 per cent of children with autism spectrum disorders suffer from chronic, severe gastrointestinal symptoms. Of those, about 75 per cent suffer from diarrhea, according to current literature.

“Little is known about the factors that predispose autistic children to C. bolteae,” said Monteiro. Although most infections are handled by some antibiotics, he said, a vaccine would improve current treatment.

“This is the first vaccine designed to control constipation and diarrhea potentially caused by C. bolteae and perhaps control autism-related symptoms associated with this microbe,” he said.

Autism cases have increased almost sixfold over the past 20 years, and scientists don’t know why. Although many experts point to environmental factors, others have focused on the human gut.

Some researchers believe toxins and/or metabolites produced by gut bacteria, including C. bolteae, may be associated with symptoms and severity of autism, especially regressive autism.

Pequegnat, a master’s student, and Monteiro used bacteria grown by Mike Toh, a Guelph microbiology PhD student.

See Also

The new anti- C. bolteae vaccine targets the specific complex polysaccharides, or carbohydrates, on the surface of the bug.

The vaccine effectively raised C. bolteae-specific antibodies in rabbits. Doctors could also use the vaccine-induced antibodies to quickly detect the bug in a clinical setting, said Monteiro.

The vaccine might take more than 10 years to work through preclinical and human trials, and it may take even longer before a drug is ready for market, Monteiro said.

Read more . . .

 

The Latest Bing News on:
Autism spectrum disorders
The Latest Google Headlines on:
Autism spectrum disorders
[google_news title=”” keyword=”autism spectrum disorders” num_posts=”10″ blurb_length=”0″ show_thumb=”left”] [/vc_column_text]
The Latest Bing News on:
Autism vaccine
    Feed has no items.
The Latest Google Headlines on:
Autism vaccine

[google_news title=”” keyword=”autism vaccine” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]

What's Your Reaction?
Don't Like it!
0
I Like it!
0
Scroll To Top